In a preclinical murine pancreatic model, they were also able to demonstrate that implants designed to co-deliver STING agonists along with CAR T cells were able to limit tumor escape, enhance survival, and elicit both local and distant anti-tumor immunity [79]. This evidence concerns the gene STING1 and neoplasm.